Write your message
Summer (In Press)                   Back to the articles list | Back to browse issues page

XML Print

1- Preventative Gynecology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran , drfarzaneh.farah@gmail.com
2- Preventative Gynecology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3- Senior Technical Manager of Nilou Laboratory, Tehran, Iran
4- CEO of Nilou Laboratory, Tehran, Iran
5- Pathology Technical Manager of Nilou Laboratory, Tehran, Iran
6- Post Quality Control Department of Nilou Laboratory, Tehran, Iran
7- Gynecologist and Obstetrician, Tehran, Iran
Abstract:   (345 Views)

Background & Objective: Cervical cancer is the second most common cancer and the fourth leading cause of death in women. Among the risk factors for cervical cancer, human papillomavirus (HPV) is the most important one.
Materials & Methods: In this cross-sectional and retrospective study conducted from 2016 to 2020, 261 women with cervical intra-epithelial neoplasia (CIN) grade two and three referred to one of the gynecological oncology clinics of Shahid Beheshti University of Medical Sciences, who were eligible to enter the study and were evaluated by the research unit of the relevant university after receiving an ethics code. During the study, patients whose cervical cancer was confirmed by colposcopic diagnostic method, HPV screening was performed by COBAS method and lesions were sampled to determine the type of HPV.
Results: Evaluation of the frequency distribution of colposcopic results compared to HPV, indicated that HPV-16 is the most common type of HPV in high grade CIN lesions. After HPV-16, other types of HPV are next in terms of frequency indicating the importance of other types of HPV. HPV-18 was also observed in people with CIN.
Conclusion: Performing a similar study with a larger number of samples at the national level is suggested. If the results of a larger study are consistent with this study, it would be for the best to highlight the role of other types of HPV in cervical cancer screening in women.

Systematic Review: Original Research | Subject: Gynecology Oncology
Received: 2021/04/8 | Accepted: 2021/04/12

1. Haghshenas M, Rafiei Alir, Zabihian F, Naghshvar F. Frequency of epstein barr virus in esophageal squamous cell carcinoma biopsies in mazandaran and golestan provinces in 2008. Iran J Microbiol 2009; 3(1): 43-8.
2. Muñoz N, Bosch FX, De Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348(6): 518-27. [DOI:10.1056/NEJMoa021641] [PMID]
3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189(1): 12-9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F [DOI:10.1002/(SICI)1096-9896(199909)189:13.0.CO;2-F]
4. Pim D, Thomas M, Banks L. The function of the human papillomavirus oncogenes. In: Viruses, Cell Transformation and Cancer Grand RJA (ed). Amsterdam: Elsevier; 2001. p. 145-92. [DOI:10.1016/S0168-7069(01)05006-6]
5. Hildesheim A. Human papillomavirus variants: implications for natural history studies and vaccine development efforts. J Natl Cancer Inst 1997; 89(11): 752-3. [DOI:10.1093/jnci/89.11.752] [PMID]
6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010 Dec 15;127(12):2893-917. [DOI:10.1002/ijc.25516] [PMID]
7. Ferlay J ,Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013 Apr;49(6):1374-403. [DOI:10.1016/j.ejca.2012.12.027] [PMID]
8. WHO. Globocan 2012: estimated cancer incidence and mortality and prevalenc worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.
9. Health IMo. Iran Cancer Report 2009. Tehran: Cancer Registration Office;2012.
10. Centers for Disease Control and Prevention. Gynecologic Cancers: Cervical cancer risk factors. Page last updated: September 3, 2013.
11. Karimy M, Hasani M, Khorram R, et al. The effect of education based on of Health Belief Model on breast self-examination in the health volunteers in Zarandieh. Tabibe Shargh: J Zahedan Univ Med Sci 2008; 10(4):79- 87.
12. Nojomi M, Modares M, Erfani A, et al. The frequency of cervical cancer risk factors in women referred to hospitals in Tehran, 2005-2006. J Iran Univ Med Sci 2007; 14(56): 189-95.
13. Austin LT, Farah A, Mary-Jane M, et al. Breast and cervical cancer screening in Hispanic women: a literature review using the Health Belief Model. Women Health Issues 2002; 12(3): 208-16. [DOI:10.1016/S1049-3867(02)00132-9]
14. Wong LP, Wong YL, Low WY, et al. Knowledge and awareness of cervical cancer and screening among Malaysian women who have never had a Pap smear: a qualitative study. Singapore Med J 2009; 50(1): 49-53.
15. Tabeshian A, Firoozeh F. The effect of health education on performing Pap smear test for prevention of cervix cancer in teachers of Isfahan City. J Azad Univ Med Sci North Branch 2009; 19(1): 43-8.
16. Society of Family Planning of Islamic Republic of Iran. Public education of fertility health. Tehran: Andishmand publ; 2001: 6-49.
17. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63(RR-05):1-30.
18. Bzhalava D. Human papillomavirus reference clones. International Human Papillomavirus Reference Center. Available at: URL: http://www.hpvcenter.se/html/refclones.html, consulté en septembre; 2014.
19. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012; 30(Suppl 5):F55-70. [DOI:10.1016/j.vaccine.2012.06.083] [PMID]
20. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24(Suppl 3):S3/35-41. [DOI:10.1016/j.vaccine.2006.06.015] [PMID]
21. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 2014; 89(43):465-91.
22. Safaei A, Khanlari M, Momtahen M, Monabati A, Robati M, Amooei S, et al. Prevalence of high-risk human papillomavirus types 16 and 18 in healthy women with cytologically negative pap smear in Iran. Indian J Pathol Microbiol 2010; 53(4):681-5. [DOI:10.4103/0377-4929.72030] [PMID]
23. Shahramian I, Heidari Z, Mahmoudzadeh-Sagheb H, Moradi A, Forghani F. Prevalence of HPV infection and high risk HPV genotypes (16, 18), among monogamous and polygamous women, in Zabol, Iran. Iran J Public Health 2011; 40(3):113-21.
24. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012; 100(Pt B):1-441.

Add your comments about this article : Your username or Email:

Send email to the article author

© 2021 CC BY-NC 4.0 | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.